Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience

Figure 1 Determination of the clinicopathological factors predicting time to progression during surveillance of metastatic pancreatic neuroendocrine tumors. A: Tumor burden of liver metastasis; B: Largest axis of the liver metastasis; C: T stage; D: M stage at diagnosis; E: Grade of liver metastasis; F: Grade of the primary tumor; G: Resection/transcatheter arterial chemoembolization of the liver metastasis; H: Resection of the primary tumor; I: Resection of the primary tumor in patients with stage IV disease. PanNET: Pancreatic neuroendocrine tumor; TACE: Transcatheter arterial chemoembolization; PD: Progressive disease.

Figure 2 Magnetic resonance imaging screening showing an example of the largest axis of a liver metastasis < 5 mm. A: Patient MRI scan image in 2017 August and 2018 October. B: Patient magnetic resonance imaging (MRI) scan image in 2017 April and 2018 March.

Figure 3 Risk stratification for predicting time to progression during surveillance on Kaplan-Meier survival curves of patients with metastatic pancreatic neuroendocrine tumors. PD: Progressive disease.

Figure 4 Nomogram for predicting time to progression during surveillance of metastatic pancreatic neuroendocrine tumors based on our proposed model. Largest axis of the liver metastasis, T stage, and resection of the primary tumor. PFS: Progression-free survival.